Japan’s pharmaceutical regulatory landscape is undergoing significant transformation in 2025, driven by a collective push to reduce Japan’s drug lag, enhance clinical trial systems, modernize post-approval processes, and support innovative therapies. These changes – initiated by the Ministry of Health, Labour and Welfare (MHLW), the Pharmaceuticals and Medical Devices Agency (PMDA), and other regulatory entities – aim to streamline drug development, accelerate access to novel therapies, and align Japan’s regulatory frameworks with global best practices.

Surge in Novel Drug Approvals and Pricing Rounds

Japan anticipates a marked increase in the number of new pharmaceutical products entering the market in 2025. Based on the latest survey incorporating industry feedback, regulatory disclosures, and information from the Japan Pharmaceutical Manufacturers Association, a total of 43 innovative medicines are projected to receive marketing approval and National Health Insurance (NHI) pricing designation this year.

This increase reflects Japan’s intent to address its long-standing issue of delayed drug access compared to Western countries. Among the pipeline of novel therapies are gene therapies, antibody-drug conjugates, oncological treatments, and high-cost orphan medicines. Of the anticipated 43 approvals, 15 products have already been authorized and are expected to be assigned prices soon, while the remaining candidates are under active regulatory review.

Global pharmaceutical firms such as Pfizer, MSD, Janssen (a Johnson & Johnson company), and Santen are among the key players with novel products in Japan’s approval queue. Chugai and Pfizer, in particular, are advancing gene therapies that rely on adeno-associated virus (AAV) vectors – an emerging category of one-time treatments with substantial cost implications. Although reimbursement bodies in Japan have historically been amenable to covering innovative drugs, the coming year will test whether Japan’s price-setting body, Chuikyo, is willing to accommodate the exceptionally high costs associated with these advanced modalities.

In a related effort to expedite market access, Japan has increased the number of annual opportunities to assign drug pricing from four times to seven. This reform is designed to minimize the time between approval and reimbursement, ensuring that life-saving drugs reach patients faster.

Shift Toward Annual Reports for Minor Manufacturing Changes

In February 2025, the MHLW initiated a trial policy that allows companies to report certain post-approval manufacturing changes via annual summaries rather than immediate notifications. The new system, which could soon become part of a revised Pharmaceuticals and Medical Devices Act, is expected to ease regulatory burdens on companies while maintaining oversight of product quality.

Previously, all minor changes affecting drug product manufacturing – classified as “minor change notifications” – had to be formally submitted. Under the trial program, certain modifications can now be captured in annual reports. Examples include specific parameter changes in manufacturing processes, revisions in labeling or test methods, and additions of external testing or storage facilities.

To ensure compliance and alignment with quality expectations, marketing authorization holders are permitted to consult with the PMDA before selecting this new reporting pathway. Notably, during the trial period, companies still have the option to file traditional notifications, if they prefer. Ultimately, this flexibility is aimed at making regulatory compliance more efficient while ensuring that quality and safety standards are preserved.

Tailored On-site GCP Inspections Based on Facility History

Effective January 31, 2025, the PMDA has revised how it conducts on-site inspections for compliance with Good Clinical Practice (GCP). The updated framework introduces a risk-based approach that tailors inspection intensity to the historical performance of each clinical trial site.

Facilities with a strong track record of compliance will benefit from a lighter inspection protocol. These facilities may be exempt from providing certain standard documents such as operational manuals of ethics committees or summaries of facility qualifications. Instead, inspections will focus on verifying investigational product management, brief discussions with clinical staff, document storage practices, and select document reviews.

Conversely, sites with a history of compliance concerns will undergo more extensive audits. These in-depth inspections will include face-to-face interviews with study investigators and clinical teams and a broader review of trial documentation. The PMDA will notify facilities in advance if they are subject to the expanded inspection process and what additional materials will be required.

This approach also extends to post-marketing clinical trial inspections, with more rigorous scrutiny planned for facilities with poor previous performance. By allocating resources based on historical risk, the PMDA aims to enhance oversight efficiency and focus attention where it is most needed.

MHLW’s Six-Point Plan to Improve Clinical Trial Infrastructure

On March 18, 2025, Japan’s MHLW laid out a comprehensive strategy to strengthen the country’s clinical research ecosystem. The plan is grounded in six strategic objectives:

Enhance Local Clinical Trial Systems: Japan is aiming to elevate the quality and global competitiveness of its domestic trials. This includes fostering early-phase research and adopting international standards for trial design and execution.
Facilitate Decentralized and Data-Driven Trials: The government intends to build infrastructure to support decentralized clinical trials (DCTs) and encourage the use of real-world data in regulatory submissions.
Leverage Technology and Reduce Costs: Japan plans to promote centralized Institutional Review Boards (IRBs) and greater use of artificial intelligence and machine learning to streamline trial oversight and data analysis.
Implement Fair Market Value (FMV) Principles: Inspired by Western standards, the MHLW seeks to adopt FMV frameworks for clinical trial payments to ensure transparency and reduce excessive spending.
Incentivize Research Participation: Japan will invest in the development of clinical research personnel and offer financial or career-related incentives to physicians and hospitals that take part in studies.
Centralize Trial Information for Public Access: Finally, efforts will be made to aggregate and publicize information about ongoing trials to make it easier for patients to learn about participation opportunities.

The MHLW intends to continue these discussions with stakeholders and release a detailed report later in the year to formalize these clinical trial priorities.

Regulatory Support for Pediatric Drug Development

In a separate move, the PMDA issued a notification on March 21, 2025, to encourage the development of medicines for pediatric populations. The agency pledged to offer more robust consultation services to pharmaceutical companies undertaking pediatric programs. These consultations will cover everything from study design to indications and clinical protocols.

The PMDA also expressed support for Japanese companies joining global pediatric clinical studies initiated in the U.S. or Europe. By aligning with multinational trials, Japan aims to accelerate access to therapies for children and expand the availability of age-appropriate formulations.

Building a Framework for Decentralized Clinical Trials

In line with global trends and as mentioned above, Japan is making strides to embrace decentralized clinical trials. Historically, the country has limited most trials to large hospitals in urban centers, requiring patients to travel extensively to participate. This centralized model has discouraged enrollment, especially for rare or genetic conditions.

Recognizing these limitations, regulators and policymakers are working to create a more inclusive and flexible clinical trial environment. Under the emerging DCT framework, Japan seeks to promote the use of home-based care, virtual visits, remote data collection, and electronic consent systems. These tools are expected to reduce patient burden and make it easier for diverse populations to enroll in trials.

Vendors and sites will be required to meet specific compliance standards to participate in decentralized trials, and sponsors will be encouraged to adopt validated digital platforms to ensure data quality and trial integrity.

Conclusion

2025 has been a pivotal year for pharmaceutical regulation in Japan. From expanding drug approvals and easing post-marketing obligations to strengthening clinical trial capabilities and investing in pediatric and decentralized research, the country is taking bold steps to modernize its approach. These reforms are not only designed to accelerate innovation but also ensure that Japanese patients can benefit from cutting-edge therapies more quickly and efficiently than ever before.

As Japan continues to align with global regulatory practices while responding to domestic healthcare needs, stakeholders in the pharmaceutical industry should remain attentive to these shifts. Proactive engagement with Japan’s evolving regulatory framework will be essential for companies seeking to bring novel treatments to one of the world’s most advanced healthcare markets.

Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)

Mr. Gross founded PBM in 1988 and has helped hundreds of medical companies with regulatory and business development issues in Asia. He is recognized nationally and internationally as a leader in the Asian medical markets. Mr. Gross has a BA degree, Phi Beta Kappa, from the University of Pennsylvania and an MBA from Columbia University.